Curry and colleagues tested an artificial intelligence (AI) software that guided non-radiology specialists in diagnosing ...

In this microsimulation model of patients with high cardiovascular risk, an intensive systolic blood pressure (SBP) target of ...

In this systematic review and meta-analysis, estimated blood pressure was found to vary significantly between different ...

Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant ...

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

Higher Post-operative Day 1 (POD1) pain scores were independently associated with increased 30-day infectious and ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety ...

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

Patients with severely disturbed sleep had the highest comorbidity burden, lowest ejection fraction, and poorest cognitive ...